/
•
•
Context is everything.
Detailed stories on technology startups, business and economic current affairs.
Detailed stories on technology startups, business and economic current affairs.
From making condoms to steering clear of costly formulations, the drugmaker’s strategy of taking the road less travelled could now give it a seat at the high table.
A fortnight ago, when Delhi-based Mankind Pharma published its first ever annual report after its public listing in May, it said it sold a whopping 52 crore Manforce condoms in 2022-23. That’s 16 a second. That business alone brought in a revenue of Rs 427 crore during the fiscal. Add sales of pregnancy testing kits and oral contraceptives and it was a further Rs 540 crore. The two together accounted for 11.5% of the company’s Rs 8,127 crore revenue.
Clearly, Mankind’s consumer business is a winner. One that is helping the company prove its critics wrong. Because, when it started …
The drugmaker’s reluctance to part with cash may have given it one of the strongest balance sheets in Indian pharma, but investors are increasingly rewarding risk takers.
A couple of antibiotics that have the potential to change the beleaguered company’s fortunes need a quick infusion of funds to get across the finish line. Can Khorakiwala, the 82-year-old chairman, pull it off?
With a promoter who is unafraid to make bold bets and pivot to businesses holding more promise, investors can only look forward to better times.
